Abstract
The B-cell-receptor (BCR) pathway, which includes Bruton’s-Tyrosine-Kinase (Btk) protein, regulates proliferation, differentiation, and apoptosis of B-cells. In B-cell malignancies such as chronic lymphocytic leukemia (CLL), aberrant BCR signaling plays critical role in pathogenesis of disease. Ibrutinab is irreversible Btk inhibitor that prevents downstream activation of the BCR pathway and subsequent proliferation of malignant B-cells. In this case report, patient with history of Ibrutinab use for several years for CLL treatment had rare adverse effect (AE) of Ibrutinib-inducted-polyneuropathy, which was only reported once in literature.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
